Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
November 07 2024 - 1:00AM
Business Wire
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that the
Company will hold a conference call on Wednesday, November 13,
2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business
progress during the third quarter of 2024.
Participants during the call will be:
- Jonathan Dickinson, Chief Executive Officer
- Sonia Quaratino, Executive Vice President, Chief Medical
Officer
- Yannis Morel, Executive Vice President, Chief Operating
Officer
- Frédéric Lombard, Senior Vice President, Chief Financial
Officer
- Arvind Sood, Executive Vice President, President of US
Operations
Details for the Virtual
Event
The live webcast will be available at the
following link:
https://events.q4inc.com/attendee/381945831
Participants may also join via telephone using the following
registration link:
https://registrations.events/direct/Q4I280043
This information can also be found on the Investors section of
the Innate Pharma website, www.innate-pharma.com. A replay of the
webcast will be available on the Company website for 90 days
following the event.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through three therapeutic approaches: monoclonal antibodies,
multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK
cell Engager Therapeutics) proprietary platform and Antibody Drug
Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, several ANKET® drug candidates to
address multiple tumor types as well as IPH4502 a differentiated
ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website
www.innate-pharma.com, and public filings and reports filed with
the U.S. Securities and Exchange Commission (“SEC”), including the
Company’s Annual Report on Form 20-F for the year ended December
31, 2023, and subsequent filings and reports filed with the AMF or
SEC, or otherwise made public by the Company. References to the
Company’s website and the AMF website are included for information
only and the content contained therein, or that can be accessed
through them, are not incorporated by reference into, and do not
constitute a part of, this press release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241106533289/en/
For additional information, please contact: Investors Innate Pharma Henry Wheeler
Tel.: +33 (0)4 84 90 32 88 Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Dec 2023 to Dec 2024